Reneo Pharmaceuticals, Inc. has announced a merger agreement where OnKure, Inc. will become a wholly owned subsidiary and the combined company will change its name to "OnKure Therapeutics, Inc." Reneo filed a registration statement, which is now effective, and a final proxy statement/prospectus seeking shareholder approval for the merger. Two legal complaints have been brought against Reneo in New York alleging misrepresentation and omission of material information related to financial projections for Reneo and OnKure, alongside potential conflicts of interest with financial advisors. Reneo intends to defend vigorously against these complaints but has opted to supplement certain disclosures in the proxy statement/prospectus without conceding any legal merit to the complaints. The updated disclosures do not imply any material changes to previous statements. The merger completion is subject to conditions that include regulatory approvals. Forward-looking statements included in the report relate to the merger's expected benefits, as well as future financial and operating results. The company cautions against undue reliance on these projections and notes the uncertainty around the merger's conclusion.
Proper names mentioned: - Reneo Pharmaceuticals, Inc. - OnKure, Inc. - OnKure Therapeutics, Inc. - Radiate Merger Sub I, Inc. - Radiate Merger Sub II, LLC - Thomas v. Reneo Pharmaceuticals, Inc., et al. - Kent v. Reneo Pharmaceuticals, Inc., et al. - Leerink Partners - Evercore Group L.L.C. - LifeSci Capital LLC - Concentra - Party A, Party B, Party C, Party D, Party E, and Party F (referred to as such in the disclosed information) - Cooley (referred to as "a representative from Cooley") - Jones Day (referred to as "a representative from Jones Day") - Gregory J. Flesher (President and Chief Executive Officer of Reneo Pharmaceuticals, Inc.)